ARCHIVES

Sorafenib Targets AML Driven By Mutant FLT3 Gene

This article is from The Cancer Letter archive.

Vol. 31 No. 2 | February 29, 2008

Download PDF Visit The Full Archive

Related Articles

Nine contracts For Automated Pap Test Systems Total $1.7 Million

October 18, 1974

Cancer Research Faces A “Strategic Inflection,” NCI Director Says

April 19, 2002

Bill Pressures HCFA To Launch Project On Reimbursement for Cancer Trials

July 26, 1996

Individualized Cancer Vaccines Show 90% Survival at 6 Months

December 27, 2013

SWOG Wins Funding For H. Pylori Trial.

November 21, 2008

In Brief: Edwards Takes A Parting Shot At Cancer Program; “Forward Plan” Calls For Emphasis On Prevention

January 17, 1975